Antihypertensive combination treatment launched

Sevikar is a new fixed dose combination of amlodipine and olmesartan, indicated for the treatment of hypertension not adequately controlled by either agent alone.

Daiichi Sankyo has launched Sevikar, a new combination angiotensin II antagonist/calcium antagonist, for the management of hypertension.

A step-wise titration of the individual components is recommended before switching to Sevikar.

Sevikar is available in three combination strengths: olmesartan 20mg/amlodipine 5mg, olmesartan 40mg/amlodipine 5mg and olmesartan 40mg/amlodipine 10mg.

View Sevikar drug record

Further information: Daiichi Sankyo

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in